Objective: Since morpho-functional bi-ventricular impairment (i.e. left ventricular hypertrophy, LVH) is described in Acromegalic patients (pts), the effects of medical and surgical treatments have been previously examined. Pegvisomant (PegV) is a GH receptor antagonist, indicated for acromegalic pts with unsuccessful surgical, radiation, and/or medical treatments, with the goal of obtaining normal IGF-1 serum levels. Aim of this observational study is to evaluate the effect of PegV on left ventricularstructure. Methods: We evaluated seven consecutive pts (4 males, mean age was50.1SD 9.8 years), with active acromegaly, eligible to PegV treatment (mean disease duration before PegV: 8 years ± 3.2) by means of a 4 yy clinical and instrumental follow-up. Starting from 10 mg daily, PegV was titrated to reach the expected levels of IGF-1 for sex and age. All patients underwent to transthoracic echocardiogram (TTE) yearly from acromegaly diagnosis; in our study we considered the following TTE results: 2 years before starting PegV (T -2), at the enrolment for PegV therapy (T0) and, respectively, after two and four years of treatment (T2, T4). We compared left ventricular dimensions, geometry (LVEDD: left ventricle end-diastolic diameter; RWT: relative wall thickness) and mass (LVM and LVM index , expressed as g/h2.7). Students t test for paired data was used. Results: At six months therapy all pts normalized IGF-1 levels, which remained stable during the whole follow up. LVM and LVMi were significantly higher at T0 when compared with T-2 (before PegV: p< 0.05 for both) whereas significantly lower at T+2 (after 2 yy PegV therapy: p<0.05 vs T0 for both). The improvement trend was confirmed after 4 years PegV treatment (p<0.05 vs T0 and vs T+2 for both). Conclusions: In our study, successful PegV treatment (involving IGF-1 serum level normalization) seems to be effective in inducing a significant LV mass reduction, whereas previous treatments showed no effect (Fig.1). The observed LVM reduction after PevG treatment could play a role in improving the cardiovascular prognosis of hypertrophic acromegalic patients.

Effects of Pegvisomant on left ventricular mass in refractroy acromegalic patients. a 4 years follow-up observational study / Carlo, Moroni; Moroni, Carlo; Tolone, Stefano; Centaro, Emilio; Lopreiato, Francesco; Valente, Lucia; Tinti Maria, Denitza; Scrofani Anna, Rita; Mercuri, Valeria; Costa, Denise; Baciarello, Giacinto; Gaudio, Carlo; Gargiulo, Patrizia. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1828-0447. - STAMPA. - 10(2016), pp. 57-57. ((Intervento presentato al convegno 116th National Congress italian Society of Internal Medicine tenutosi a Roma, Italy nel 10-12 OCTOBER 2015.

Effects of Pegvisomant on left ventricular mass in refractroy acromegalic patients. a 4 years follow-up observational study

MORONI, Carlo
Writing – Original Draft Preparation
;
Mercuri Valeria;Costa Denise;BACIARELLO, Giacinto;GAUDIO, Carlo;GARGIULO, Patrizia
2016

Abstract

Objective: Since morpho-functional bi-ventricular impairment (i.e. left ventricular hypertrophy, LVH) is described in Acromegalic patients (pts), the effects of medical and surgical treatments have been previously examined. Pegvisomant (PegV) is a GH receptor antagonist, indicated for acromegalic pts with unsuccessful surgical, radiation, and/or medical treatments, with the goal of obtaining normal IGF-1 serum levels. Aim of this observational study is to evaluate the effect of PegV on left ventricularstructure. Methods: We evaluated seven consecutive pts (4 males, mean age was50.1SD 9.8 years), with active acromegaly, eligible to PegV treatment (mean disease duration before PegV: 8 years ± 3.2) by means of a 4 yy clinical and instrumental follow-up. Starting from 10 mg daily, PegV was titrated to reach the expected levels of IGF-1 for sex and age. All patients underwent to transthoracic echocardiogram (TTE) yearly from acromegaly diagnosis; in our study we considered the following TTE results: 2 years before starting PegV (T -2), at the enrolment for PegV therapy (T0) and, respectively, after two and four years of treatment (T2, T4). We compared left ventricular dimensions, geometry (LVEDD: left ventricle end-diastolic diameter; RWT: relative wall thickness) and mass (LVM and LVM index , expressed as g/h2.7). Students t test for paired data was used. Results: At six months therapy all pts normalized IGF-1 levels, which remained stable during the whole follow up. LVM and LVMi were significantly higher at T0 when compared with T-2 (before PegV: p< 0.05 for both) whereas significantly lower at T+2 (after 2 yy PegV therapy: p<0.05 vs T0 for both). The improvement trend was confirmed after 4 years PegV treatment (p<0.05 vs T0 and vs T+2 for both). Conclusions: In our study, successful PegV treatment (involving IGF-1 serum level normalization) seems to be effective in inducing a significant LV mass reduction, whereas previous treatments showed no effect (Fig.1). The observed LVM reduction after PevG treatment could play a role in improving the cardiovascular prognosis of hypertrophic acromegalic patients.
File allegati a questo prodotto
File Dimensione Formato  
Moroni_Effects_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 3.08 MB
Formato Adobe PDF
3.08 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/966986
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact